ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

3 Volatile Stocks with Questionable Fundamentals

PTON Cover Image

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Navigating these stocks isn’t easy, which is why StockStory helps you find Comfort In Chaos. That said, here are three volatile stocks best left to the gamblers and some better opportunities instead.

Peloton (PTON)

Rolling One-Year Beta: 2.58

Started as a Kickstarter campaign, Peloton (NASDAQ: PTON) is a fitness technology company known for its at-home exercise equipment and interactive online workout classes.

Why Is PTON Risky?

  1. Sluggish trends in its connected fitness subscribers suggest customers aren’t adopting its solutions as quickly as the company hoped
  2. Suboptimal cost structure is highlighted by its history of operating losses
  3. Cash-burning tendencies make us wonder if it can sustainably generate shareholder value

Peloton is trading at $6.62 per share, or 9.1x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including PTON in your portfolio.

Lovesac (LOVE)

Rolling One-Year Beta: 2.34

Known for its oversized, premium beanbags, Lovesac (NASDAQ: LOVE) is a specialty furniture brand selling modular furniture.

Why Does LOVE Worry Us?

  1. Sales trends were unexciting over the last two years as its 2.2% annual growth was below the typical consumer discretionary company
  2. Capital intensity will likely ramp up in the next year as its free cash flow margin is expected to contract by 1.5 percentage points
  3. Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability

At $21.12 per share, Lovesac trades at 45.9x forward price-to-earnings. Check out our free in-depth research report to learn more about why LOVE doesn’t pass our bar.

Elanco (ELAN)

Rolling One-Year Beta: 1.42

Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE: ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries.

Why Is ELAN Not Exciting?

  1. Weak constant currency growth over the past two years indicates challenges in maintaining its market share
  2. Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 3.1% annually
  3. Negative returns on capital show that some of its growth strategies have backfired

Elanco’s stock price of $9.50 implies a valuation ratio of 10.7x forward price-to-earnings. Dive into our free research report to see why there are better opportunities than ELAN.

Stocks We Like More

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.